May 24, 2023Open Access

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial

Key Points

Key points are not available for this paper at this time.

Abstract

No new safety signals were reported and HRQoL was maintained with 3 years of adjuvant osimertinib treatment. Combined with significant efficacy benefit, these data further support adjuvant osimertinib in stage IB to IIIA EGFR-mutated NSCLC.

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Cite This Study

John et al. (Wed,) studied this question.

synapsesocial.com/papers/69e99beb3bdd94074234816b https://doi.org/https://doi.org/10.1016/j.jtho.2023.05.015

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial2022 · 25 citations